Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 27, 2020
Daily News
August 27, 2020
- MHLW Panels Agree to Prioritize Flu Vaccinations for Elderly, and Then HCPs
August 27, 2020
- MHLW to Accept Sakigake Applications All Year Long under Amended PMD Law
August 27, 2020
- MHLW Vows Thorough Post-Approval Safety Follow-Up on COVID-19 Vaccines: Official
August 27, 2020
- 2 More HIF-PH Inhibitors, Enerzair, Enspryng and More Now Available in Japan
August 27, 2020
- JCR to Commence Full-Fledged Biz for Lysosomal Storage Disorder Meds in Brazil
August 27, 2020
- Kowa’s Glaucoma Med Glanatec Approved in Thailand
August 27, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…